Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
BCE BCE Inc
CLX Clorox Co
RSG Republic Services Inc
BANX ArrowMark Financial Corp
VQS Viq Solutions Inc
SPY SPDR® S&P 500 ETF Trust
LPTV Loop Media Inc
NUVB Nuvation Bio Inc
ATTO Atento SA
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Longeveron Inc. is a clinical-stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, such as aging related frailty, Alzheimer's disease (AD), acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Closing Price
$2.96
Day's Change
-0.05 (-1.66%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.09
Day's Low
2.95
Volume
(Light)
Volume:
7,717

10-day average volume:
32,072
7,717

Display:

Providers:

UpdateCancel
All providers
May 22, 2023
May 12, 2023
May 09, 2023
Novavax and Palantir rocket higher, while PayPal slumps and other stocks on the move

By Ciara Linnane Novavax posts positive results from a trial of flu and COVID vaccines and says it's cutting a quarter of its workforce Here are some of the biggest movers of the day on Tuesday: (MarketWatch)

Longeveron stock up 15.5% premarket after positive results in trial of treatment for rare congenital heart defect in infants

Longeveron Inc.'s stock (LGVN) rocketed 15.5% in premarket trade Tuesday, after the biotech said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome) achieved 100% survival up to 5 years of...(MarketWatch)

May 08, 2023
April 19, 2023
March 10, 2023
March 06, 2023

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.